Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nitazoxanide as an early treatment to reduce the intensity of COVID‑19 outbreaks among health personnel
Hugo Mendieta Zerón, José Meneses Calderón, Leopoldo Paniagua Coria, et al.
World Academy of Sciences Journal (2021) Vol. 3, Iss. 3
Open Access | Times Cited: 21

Showing 21 citing articles:

Nanomaterials for Photocatalytic Degradations of Analgesic, Mucolytic and Anti-Biotic/Viral/Inflammatory Drugs Widely Used in Controlling SARS-CoV-2
Mahsa Ebrahimi, Omid Akhavan
Catalysts (2022) Vol. 12, Iss. 6, pp. 667-667
Open Access | Times Cited: 59
Fast one-pot microwave-assisted green synthesis of highly fluorescent plant-inspired S,N-self-doped carbon quantum dots as a sensitive probe for the antiviral drug nitazoxanide and hemoglobin
Nermeen A. Qandeel, Amal A. El‐Masry, Manal Eid, et al.
Analytica Chimica Acta (2022) Vol. 1237, pp. 340592-340592
Closed Access | Times Cited: 55
Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics
Yash Gupta, Oleksandr V. Savytskyi, Matt Coban, et al.
Molecular Aspects of Medicine (2022) Vol. 91, pp. 101151-101151
Open Access | Times Cited: 30
NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects
Mina Kelleni
Expert Review of Anti-infective Therapy (2021) Vol. 20, Iss. 1, pp. 17-21
Open Access | Times Cited: 35
Asparagus officinalis Herb‐derived Carbon Quantum Dots: Luminescent Probe for Medical Diagnostics
Nisha Yadav, Deeksha Mudgal, Manish Kr Mishra, et al.
Chemistry & Biodiversity (2024) Vol. 21, Iss. 8
Closed Access | Times Cited: 2
Repurposing of Chemotherapeutics to Combat COVID-19
Sisir Nandi, Bhabani Shankar Nayak, Mayank Kumar Khede, et al.
Current Topics in Medicinal Chemistry (2022) Vol. 22, Iss. 32, pp. 2660-2694
Closed Access | Times Cited: 10
Strategies for drug repurposing against coronavirus targets
Poppy O. Smith, Peiqin Jin, Khondaker Miraz Rahman
Current Research in Pharmacology and Drug Discovery (2021) Vol. 3, pp. 100072-100072
Open Access | Times Cited: 12
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection
Simiso Sokhela, Bronwyn Bosch, Andrew Hill, et al.
Journal of Antimicrobial Chemotherapy (2022) Vol. 77, Iss. 10, pp. 2706-2712
Open Access | Times Cited: 8
NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory Protocol Used in Adult, Geriatric, Pediatric, Pregnant, and Immunocompromised COVID-19 Patients: A Real-World Experience
Mina Kelleni
Canadian Journal of Medicine (2021)
Closed Access | Times Cited: 10
Can Anti-Parasitic Drugs Help Control COVID-19?
Yasin Panahi, Masoomeh Dadkhah, Sahand Talei, et al.
Future Virology (2022) Vol. 17, Iss. 5, pp. 315-339
Open Access | Times Cited: 7
Outpatient treatment of COVID-19: an experience with 552 cases in Mexico
Raúl Romero-Cabello, Raúl Romero-Feregrino, Rodrigo Romero-Feregrino, et al.
The Journal of Infection in Developing Countries (2023) Vol. 17, Iss. 03, pp. 311-318
Open Access | Times Cited: 2
Can Nitazoxanide and/or other anti‐viral medications be a solution to long COVID? Case report with a brief literature review
D. Stewart
Clinical Case Reports (2023) Vol. 11, Iss. 11
Open Access | Times Cited: 2
Post COVID-19 complications, adjunct therapy explored, and steroidal after effects
Charu Sonkar, Vaishnavi Hase, Durba Banerjee, et al.
Canadian Journal of Chemistry (2022) Vol. 100, Iss. 7, pp. 459-474
Open Access | Times Cited: 4
Evolution of COVID-19 Pregnancies Treated With Nitazoxanide in a Third-Level Hospital
Krista Yazareth Enríquez López, José Meneses Calderón, Lilia De la Cruz Ávila, et al.
Cureus (2021)
Open Access | Times Cited: 4
Diclofenac potassium/Nitazoxanide/Azithromycin Used in Adults, Children and Pregnant Patients: A Novel Potential Game Changer COVID-19 Protocol.
Mina Kelleni
(2021)
Closed Access | Times Cited: 3
Perspectives on Antiviral Drugs Development in the Treatment of COVID-19
Aura Rusu, Eliza Mihaela Arbănași, Ioana-Andreea Lungu, et al.
Acta Biologica Marisiensis (2021) Vol. 4, Iss. 1, pp. 44-59
Open Access | Times Cited: 2
NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory Protocol Used in Adults, Children and Pregnant COVID-19 Patients: An Egyptian Prospective Observational Study.
Mina Kelleni
(2021)
Open Access | Times Cited: 2
Rural treatment of COVID-19 patients with pirfenidone, nitazoxanide and colchicine. Case series
Brandon Iturbe Esquivel, José Meneses Calderón, Luis Edgar Concepción-Carrillo, et al.
Monaldi Archives for Chest Disease (2022)
Open Access | Times Cited: 1
Non-steroidal Anti-inflammatory Drugs (NSAIDs)/nitazoxanide/azithromycin Potential Beneficial COVID-19 Effects: Preventing the Cytokine Storm via Mitigation of the Interleukin-6 Amplifier and Monocytic Immunological Dysrhythmia.
Mina Kelleni
(2021)
Closed Access | Times Cited: 1
An in silico study on inhibitability of Baloxavir marboxil, Baricitinib, Galidesivir, Nitazoxanide, and Oseltamivir against SARS‐CoV‐2
Thanh Q. Bui, Nguyễn Thị Thanh Hải, Tran Thi Ai My, et al.
Vietnam Journal of Chemistry (2022) Vol. 60, Iss. 3, pp. 333-345
Open Access
Role of Immunity and Inflammation Mediators in Early COVID-19 Management: Genetic Results Interpretations Versus Real-life Practice.
Mina Kelleni
(2021)
Closed Access
Page 1

Scroll to top